Duquesne Family Office - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 157 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.96 and the average weighting 1.1%.

Quarter-by-quarter ownership
Duquesne Family Office ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$6,937
-33.0%
906,767
-34.6%
0.25%
-30.8%
Q2 2023$10,353
+11.8%
1,385,9500.0%0.36%
-10.2%
Q1 2023$9,259
-99.9%
1,385,9500.0%0.40%
-24.2%
Q4 2022$10,685,675
-27.5%
1,385,9500.0%0.53%
-36.7%
Q3 2022$14,747,000
+561.9%
1,385,950
+406.5%
0.84%
+419.3%
Q2 2022$2,228,000
+13.7%
273,6500.0%0.16%
+89.4%
Q1 2022$1,959,000
-56.0%
273,650
+5.3%
0.08%
-47.2%
Q4 2021$4,453,000
-25.5%
259,9410.0%0.16%
-17.0%
Q3 2021$5,981,000259,9410.19%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q2 2023
NameSharesValueWeighting ↓
Kinnevik AB (publ) 10,405,668$77,730,340100.00%
Data Collective IV GP, LLC 5,941,120$44,380,16632.86%
MV Management XI, L.L.C. 1,971,908$14,730,15325.77%
MIC Capital Management UK LLP 8,451,758$63,134,63512.84%
Yong Rong (HK) Asset Management Ltd 1,174,200$8,7723.85%
ArchPoint Investors 1,114,626$8,326,2563.22%
PLATINUM INVESTMENT MANAGEMENT LTD 2,711,148$20,252,2760.70%
HARVARD MANAGEMENT CO INC 882,129$6,5900.65%
Diametric Capital, LP 119,906$895,6980.40%
Lingotto Investment Management LLP 775,077$5,789,8250.37%
View complete list of RECURSION PHARMACEUTICALS IN shareholders